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1. Introduction {#ehf212605-sec-0004}
===============

Syncopal episodes are a common medical problem in patients with cardiovascular diseases. Syncope is defined as a transient loss of consciousness due to cerebral hypoperfusion, characterized by a rapid onset, short duration, and spontaneous complete recovery---often caused by alterations in pathophysiology, for example, arrhythmia, vegetative dysregulation, or haemodynamic changes.[1](#ehf212605-bib-0001){ref-type="ref"} All these entities are also altered in heart failure (HF).[1](#ehf212605-bib-0001){ref-type="ref"}, [2](#ehf212605-bib-0002){ref-type="ref"}, [3](#ehf212605-bib-0003){ref-type="ref"} Patients suffering from HF account for nearly 1--2% of the adult population in developed countries, rising up to ≥10% among people above 70 years of age with a still very poor outcome.[2](#ehf212605-bib-0002){ref-type="ref"}, [4](#ehf212605-bib-0004){ref-type="ref"} Syncope associated with cardiovascular disease may have a poor prognosis.[5](#ehf212605-bib-0005){ref-type="ref"} Hence, we sought to investigate whether the history of syncope (HoS) has an impact on the survival of patients suffering from HF.

Regarding the latest guidelines, patients with HF are mainly categorized into HF with reduced ejection fraction (HFrEF), HF with mid‐range ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF) due to different underlying aetiologies, demographics, co‐morbidities, and response to therapies.[2](#ehf212605-bib-0002){ref-type="ref"}, [6](#ehf212605-bib-0006){ref-type="ref"} All three entities present with altered systolic left ventricle (LV) function; although the left ventricle ejection fraction (LVEF) remains preserved among patients with HFpEF, their prevalence and prognoses are comparable.[7](#ehf212605-bib-0007){ref-type="ref"}

Observations showed that patients with HFrEF are predominantly at risk for fatal arrhythmia and sudden cardiac death.[8](#ehf212605-bib-0008){ref-type="ref"}, [9](#ehf212605-bib-0009){ref-type="ref"} Data from small cohorts suggested an association of HoS of any origin with a higher burden for fatal arrhythmia and sudden cardiac death among HFrEF cohorts.[10](#ehf212605-bib-0010){ref-type="ref"}

Syncopal episodes are associated not only with arrhythmia but also with LV dysfunction---even regardless of the LVEF.[11](#ehf212605-bib-0011){ref-type="ref"} Patients with HF with syncopal episodes show more often LV dysfunction than patients with HF without HoS. Nonetheless, a previous study examining a large HFpEF cohort suggested to evaluate the impact of syncopes especially in this population based on trends they could observe.[12](#ehf212605-bib-0012){ref-type="ref"}

Because syncopal episodes are a widespread condition with a lifetime cumulative incidence as high as 35% in the general population[5](#ehf212605-bib-0005){ref-type="ref"}, further analyses challenging these findings in a cohort of patients with HF are required.

We therefore aimed to assess the prevalence and prognostic utility of HoS in patients with HF. We hypothesized that HoS is associated with worse survival and shorter time to hospitalization in patients with HF.

2. Methods {#ehf212605-sec-0005}
==========

2.1. Study design and setting {#ehf212605-sec-0006}
-----------------------------

The German Competence Network for HF (CNHF) constitutes one of Europe\'s largest HF research programmes. Its rationale and design have been previously described.[13](#ehf212605-bib-0013){ref-type="ref"} It is a prospective, nationwide, multicentre framework of observational cohort and interventional studies aiming to describe clinical characteristics and mechanisms leading to and accelerating HF and elucidating therapeutic implications. From the beginning of the CNHF, a uniform basic clinical dataset for all studies was complemented containing 190 predefined items that were collected by all subjects included in CNHF studies.[13](#ehf212605-bib-0013){ref-type="ref"} This approach allows for pooled data analysis of study results. Standardized case report forms, centrally run databases with automated revision and consistency checks and development of standard operating procedures for all pertinent workflows, further support the process of high‐quality data collection and analysis.[13](#ehf212605-bib-0013){ref-type="ref"}

2.2. Study sample {#ehf212605-sec-0007}
-----------------

From a pooled database with 11 335 subjects from the 20 prospective HF studies of the German CNHF, five studies provided details of a 10 year follow‐up (5318 subjects). One trial of those focused only in patients with an HIV infection and alterations of their cardiac function. Because this HIV only population might change our pooled cohort due to the con‐medication and potential other confounders, we excluded this study and focused on the remaining four studies with 4443 subjects (Diast‐CHF, IKARIUS, CIBIS‐Eld, and INH).[14](#ehf212605-bib-0014){ref-type="ref"}, [15](#ehf212605-bib-0015){ref-type="ref"}, [16](#ehf212605-bib-0016){ref-type="ref"}, [17](#ehf212605-bib-0017){ref-type="ref"} Here, 438 subjects were missing on follow‐up details, and 411 were not completed in key parameters (e.g. echocardiography details such as LVEF or E/e′, aortic valve stenosis, and electrocardiogram (ECG) details; for more details, see Appendix [A](#ehf212605-app-0001){ref-type="app"}). Therefore, we analysed 3594 subjects in total, including 2130 patients with HF (HFrEF: *n* = 1564, HFmrEF: *n* = 314, and HFpEF: *n* = 252) and 1464 subjects without HF, who we considered as controls.

Heart failure with reduced ejection fraction was defined as the diagnosis of HF and LVEF \<40%, HFmrEF as the diagnosis of HF and 40% \> LVEF \< 50%, and HFpEF as the diagnosis of HF and LVEF \>50% at the time of study inclusion.

All studies included complied with the Declaration of Helsinki; the protocols were approved by the responsible Ethics Committees, and all patients gave written informed consent.

2.3. Endpoint {#ehf212605-sec-0008}
-------------

The endpoints in focus were defined as time to mortality from any cause or time to first hospitalization (hospitalization‐free survival).

Death and hospitalizations, including date and diagnoses, were documented and reported throughout all studies at personal or telephone visits. Patients who were lost to follow‐up were excluded from the analysis.

2.4. Statistical methods {#ehf212605-sec-0009}
------------------------

Study cohort and subgroups are described by number (%) for categorical data and by mean (standard deviation) for most scale variables. For the skew distributed N terminal pro brain natriuretic peptide (NT‐proBNP) values, median, lower quartile, and upper quartile are presented.

We compared frequencies by *χ* ^2^ test. Inverse survival curves for mortality and hospitalization were calculated and plotted by the Kaplan--Meier method. Groups were compared by log‐rank test. Observation times were truncated at 126 months.

Searching baseline variables associated with (hospitalization‐free) survival time, we built multivariable Cox regression models. Starting with the variables from *Table* [1](#ehf212605-tbl-0001){ref-type="table"}, we excluded irrelevant variables by backward selection using the Akaike information criterion. Final models were built with the variables selected that way to obtain correct estimates for the hazard ratio (HR). Odds ratios and HRs were calculated including 99% confidence interval.

###### 

Baseline characteristics of the population analysed based on HF entities

                                   No HF   HFrEF            HFmrEF   HFpEF            Total                                                   
  -------------------------------- ------- ---------------- -------- ---------------- ------- ---------------- ------ ---------------- ------ --------------
  History of syncope               187     12.8%            234      15.0%            40      12.7%            23     25.0%            524    14.6%
  Age                              65.5    8.3              66.3     13.3             70.2    9.6              72.3   7.1              66.7   11.0
  Female sex                       758     51.8%            435      27.8%            82      26.1%            159    63.1%            1434   39.9%
  BMI                              28.7    4.7              27.0     4.7              27.8    4.4              29.5   5.2              27.9   4.8
  HR (at rest, 1/min)              71      12               74       13               73      13               68     12               72     12
  Systolic BP                      147     22               123      19               135     20               147    23               135    24
  Diastolic BP                     83      12               74       12               79      12               81     13               79     12
  Medical history                                                                                                                             
  Diabetes mellitus                327     22.3%            480      30.7%            88      28.0%            67     26.6%            962    26.8%
  Hypertension                     1157    79.0%            1066     68.2%            260     82.8%            230    91.3%            2713   75.5%
  Hyperlipidaemia                  570     38.9%            872      55.8%            201     64.0%            147    58.3%            1790   49.8%
  Hyperuricaemia                   185     12.6%            626      40.0%            70      22.3%            45     17.9%            926    25.8%
  Family history of MI             182     12.4%            254      16.3%            50      15.9%            41     16.3%            527    14.7%
  Smoking---No                     752     51.4%            682      43.8%            146     46.6%            161    64.1%            1741   48.6%
  Ex‐smoker                        544     37.2%            635      40.8%            137     43.8%            68     27.1%            1384   38.6%
  Smoker                           167     11.4%            239      15.4%            30      9.6%             22     8.8%             458    12.8%
  CAD                              218     14.9%            792      50.6%            193     61.5%            82     32.5%            1285   35.8%
  MI                               102     7.0%             599      38.3%            134     42.7%            38     15.1%            873    24.3%
  Primary valve disease            7       0.5%             36       2.3%             14      4.5%             3      1.2%             60     1.7%
  Valve surgery                    8       0.5%             57       3.6%             13      4.1%             6      2.4%             84     2.3%
  RV pacemaker                     17      1.2%             147      9.4%             19      6.1%             11     4.4%             194    5.4%
  BV pacemaker                     0       0.0%             65       4.2%             6       1.9%             0      0.0%             71     2.0%
  Resuscitation                    22      1.5%             117      7.5%             15      4.8%             8      3.2%             162    4.5%
  PAOD                             56      3.8%             137      8.8%             31      9.9%             25     10.0%            249    6.9%
  Cerebro‐vascular disease         88      6.0%             172      11.0%            38      12.1%            28     11.1%            326    9.1%
  COPD                             99      6.8%             216      13.8%            31      9.9%             21     8.3%             367    10.2%
  Primary pulmonary hypertension   3       0.2%             23       1.5%             3       1.0%             3      1.2%             32     0.9%
  Depression                       140     9.6%             136      8.7%             12      3.8%             35     13.9%            323    9.0%
  Atrial fibrillation              33      2.3%             404      25.9%            71      22.8%            35     13.9%            543    15.2%
  Anaemia                          91      6.5%             411      27.0%            77      26.0%            45     18.6%            624    18.1%
  Laboratory                                                                                                                                  
  Haemoglobin (mmol/L)             8.7     .76              8.5      1.20             8.5     1.10             8.4    0.9              8.6    1.0
  Sodium (mmol/L)                  140     2.45             140      3.85             140     3.84             140    3                140    3
  Potassium (mmol/L)               4.32    0.53             4.32     0.51             4.44    0.57             4.20   0.49             4.32   0.53
  eGFR (Cock.‐Gold)                59.3    \[59.8, 83.5\]   59.3     \[45.1, 79.5\]   59.1    \[47.8, 73.5\]   62.4   \[49.6, 75.4\]   65.0   \[51, 81\]
  NT‐proBNP                        91      \[49, 175\]      2369     \[885, 6108\]    832     \[402, 1963\]    296    \[181, 616\]     321    \[96, 1729\]
  ECG                                                                                                                                         
  Rhythm---Sinus                   1409    96.6%            1027     65.8%            226     72.4%            206    82.1%            2868   80.1%
  Atrial fibrillation              32      2.2%             389      24.9%            66      21.2%            35     13.9%            522    14.6%
  Pacemaker                        14      1.0%             133      8.6%             20      6.4%             8      3.2%             175    5.1%
  Other                            4       0.3%             11       0.7%             0       0.0%             2      0.8%             17     0.5%
  Heart rate (ECG)                 67      11               79       18               74      16               67     13               72     16
  QT time                          392     32               394      57               398     48               409    37               395    46
  LBBB                             23      1.6%             478      31.1%            48      15.5%            12     4.8%             561    15.8%
  RBBB                             72      4.9%             139      9.0%             21      6.8%             28     11.2%            260    7.3%
  AV‐block                         173     11.9%            164      11.1%            31      10.4%            32     13.1%            400    11.5%
  Echocardiography                                                                                                                            
  LVEF                             61.2    6.3              29.1     7.0              42.4    2.6              60.1   7.4              45.5   16.6

BMI, body mass index; BP, blood pressure; BV pacemaker, biventricular pacemaker; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HF, heart failure; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; LBBB, left bundle branch block; LVEF, left ventricle ejection fraction; MI, myocardial infarction; NT‐proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart Association; PAOD, peripheral arterial occlusive disease; RBBB, right bundle branch block; RV pacemaker, right ventricular pacemaker; SD, standard deviation.

All tests were performed two‐tailed at significance level α = 1%. The analyses were carried out by means of IBM SPSS Statistics, version 25 and the free statistical software R, version 3.6 including the package *survival*.

3. Results {#ehf212605-sec-0010}
==========

3.1. Subject population {#ehf212605-sec-0011}
-----------------------

A total of 11 335 subjects were screened for analysis from the database; 3594 subjects were eligible and provided sufficient data for analysis (*Figure* [*1*](#ehf212605-fig-0001){ref-type="fig"}). Of them, 1564 patients were with HFrEF (43.5%), 314 (8.7%) with HFmrEF, and 252 with HFpEF (7.0%), and 1464 were subjects without HF (40.7%). We considered the subjects without HF as controls in our study. Baseline characteristics of the different HF entities as well as the controls are described in *Table* [1](#ehf212605-tbl-0001){ref-type="table"}. *Table* [2](#ehf212605-tbl-0002){ref-type="table"} describes the characteristics of the cohort with HoS versus the cohort without HoS.

![Patient flow chart (patients from the pooled databases). CNHF, Competence Network for Heart Failure; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction. ^\*^Not all studies provided the same inclusion and exclusion criteria; if basic data were missing according to our protocol, they were excluded (see Appendix [A](#ehf212605-app-0001){ref-type="app"}).](EHF2-7-942-g001){#ehf212605-fig-0001}

###### 

Baseline characteristics of the population analysed based on the presence of HoS

                                      No HoS               HoS                 Total            Cohen\'s *d*                   
  ----------------------------------- -------------------- ------------------- ---------------- -------------- ------- ------- -------
  Age                                 66.5                 11.0                68.1             10.9           66.7    11.0    0.15
  Female sex                          1208                 39.3%               226              43.1%          1434    39.9%   0.86
  BMI                                 28.0                 4.8                 27.7             4.8            27.9    4.8     −0.05
  HR (at rest,)                       72                   12                  71               13             72      12      −0.12
  Systolic BP (mmHg)                  136                  24                  134              25             135     24      −0.09
  Diastolic BP (mmHg)                 79.1                 12.3                77.1             13.3           78.8    12.5    −0.16
  NYHA I                              110                  6.1%                16               4.7%           126     5.9%    ---
  NYHA II                             990                  55.2%               165              49.0%          1155    54.3%   
  NYHA III                            645                  36.0%               146              43.3%          791     37.2%   
  NYHA IV                             47                   2.6%                10               3.0%           57      2.7%    
  Medical history                                                                                                              
  Diabetes mellitus                   829                  27.0%               133              25.4%          962     26.8%   1.09
  Hypertension                        2303                 75.0%               410              78.2%          2713    75.5%   0.83
  Hyperlipidaemia                     1491                 48.6%               299              57.1%          1790    49.8%   0.71
  Hyperuricaemia                      752                  24.5%               174              33.2%          926     25.8%   0.65
  Family history of MI                426                  13.9%               101              19.3%          527     14.7%   0.67
  Smoking---No                        1471                 48.1%               270              51.6%          1741    48.6%   ---
  Ex‐smoker                           403                  13.2%               55               10.5%          458     12.8%   
  Smoker                              1186                 38.8%               198              37.9%          1384    38.6%   
  CAD                                 1084                 35.3%               201              38.4%          1285    35.8%   0.88
  MI                                  744                  24.2%               129              24.6%          873     24.3%   0.98
  Primary valve disease               49                   1.6%                11               2.1%           60      1.7%    0.76
  Valve surgery                       67                   2.2%                17               3.2%           84      2.3%    0.67
  RV pacemaker                        134                  4.4%                60               11.5%          194     5.4%    0.35
  BV pacemaker                        48                   1.6%                23               4.4%           71      2.0%    0.35
  Resuscitation                       96                   3.1%                66               12.6%          162     4.5%    0.22
  PAOD                                200                  6.5%                49               9.4%           249     6.9%    0.68
  Cerebro‐vascular disease            255                  8.3%                71               13.5%          326     9.1%    0.58
  COPD                                295                  9.6%                72               13.7%          367     10.2%   0.67
  Primary pulmonary hypertension      20                   0.7%                12               2.3%           32      0.9%    0.28
  Depression                          242                  7.9%                81               15.5%          323     9.0%    0.47
  Atrial fibrillation                 464                  15.2%               79               15.2%          543     15.2%   1.00
  Anaemia                             529                  18.0%               95               18.6%          624     18.1%   0.94
  Laboratory                                                                                                                   
  Haemoglobin (mmol/L)                8.58                 1.03                8.52             0.99           8.58    1.02    −0.06
  Sodium (mmol/L)                     140.1                3.3                 139.5            3.4            140.0   3.4     −0.17
  Potassium (mmol/L)                  4.34                 0.52                4.25             0.53           4.32    0.53    −0.17
  eGFR (Cock.‐Gold, ml/min/1.73 m²)   66 \[52. 81\]        63 \[47. 77\]       65 \[51. 81\]    0.45                           
  NT‐proBNP                           316 \[92.5. 1651\]   339 \[125. 2027\]   321 \[96. 1729   0.53                           
  ECG                                                                                                                          
  Rhythm---Sinus                      2475                 80.9%               393              75.4%          2868    80.1%   ---
  Atrial fibrillation                 449                  14.7%               73               14.0%          522     14.6%   
  Pacemaker                           28                   0.9%                13               2.5%           41      1.1%    
  Other                               13                   0.4%                4                0.8%           17      0.5%    
  Heart rate (ECG, bpm)               73                   16                  72               16             72      16      −0.07
  QT time                             394                  45                  402              49             395     46      0.18
  LBBB                                460                  15.1%               101              19.6%          561     15.8%   0.74
  RBBB                                211                  6.9%                49               9.5%           260     7.3%    0.72
  Echocardiography                                                                                                             
  LVEF                                45.5                 16.5                45.8             17.4           45.5    16.6    0.02

BMI, body mass index; BP, blood pressure; BV pacemaker, biventricular pacemaker; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HF, heart failure; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HoS, history of syncope; HR, hazard ratio; LBBB, left bundle branch block; LVEF, left ventricle ejection fraction; MI, myocardial infarction; NT‐proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart Association functional class; PAOD, peripheral arterial occlusive disease; RBBB, right bundle branch block; RV pacemaker, right ventricular pacemaker; SD, standard deviation.

3.2. Prevalence of history of syncope {#ehf212605-sec-0012}
-------------------------------------

Of all the subjects, 14.6% (524/3594) reported HoS (*Table* [2](#ehf212605-tbl-0002){ref-type="table"}). Patients with HFrEF in our pooled cohort showed more often syncopes than subjects without HF (15.0% vs. 12.8%, *P* = 0.082) and more than with patients with HFmrEF (15.0% vs. 12.7%, *P* = 0.31) but distinctly less than with patients with HFpEF (15.0% vs. 25.0%, *P* \< 0.001). HoS was most prevalent among patients with HFpEF.

3.3. Overall and hospitalization‐free survival {#ehf212605-sec-0013}
----------------------------------------------

Among all subjects, those with HoS showed a worse 126 month survival \[57.6% vs. 62.1%, HR = 1.17, 99% confidence interval (0.96, 1.41), *P* = 0.038\] (*Figure* [*2*](#ehf212605-fig-0002){ref-type="fig"}) and a worse hospitalization‐free survival up to 126 months follow‐up \[43.1% vs. 45.5%, HR = 1.15, 99% confidence interval (0.98, 1.35), *P* = 0.03\]. However, both are not significant at the 1% level.

![Ten year overall survival in the HF and control cohorts. HF, heart failure; HFmrEF, HF with mid‐range ejection fraction; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; HoS, history of syncope.](EHF2-7-942-g002){#ehf212605-fig-0002}

Among all patients with HFrEF, those with HoS showed a worse overall survival than those without HoS \[30.3% vs. 41.6%, HR = 1.40, 99% confidence interval (1.12, 1.74), *P* \< 0.001; *Figure* [*2*](#ehf212605-fig-0002){ref-type="fig"}\]. Also, hospitalization‐free survival was altered in the same manner in this cohort \[with HoS: 21.8%, without HoS: 31.2%, HR = 1.49, 99% confidence interval (1.21, 1.83); *Figure* [*3*](#ehf212605-fig-0003){ref-type="fig"}\].

![Hospitalization‐free survival within a 10 year follow‐up in all cohorts. HF, heart failure; HFmrEF, HF with mid‐range ejection fraction; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; HoS, history of syncope.](EHF2-7-942-g003){#ehf212605-fig-0003}

Exploring the data of patients with HFmrEF and HFpEF resulted in no significant difference in overall or hospitalization‐free survival between patients with HoS and patients without HoS (HFmrEF: *P* = 0.85; HFpEF: *P* = 0.48).

3.4. Assessment of added single value to syncopes {#ehf212605-sec-0014}
-------------------------------------------------

We analysed the characteristics and risk factors associated with the endpoints in patients with HFrEF, HFmrEF, and HFpEF as well as in patients without HF separately (*Table* [3](#ehf212605-tbl-0003){ref-type="table"}).

###### 

Factors associated with mortality and hospital‐free survival.

                                                                                                           Hazard ratio   99% confidence interval   *P* value   
  -------------------------------------------------------------------------------------------------------- -------------- ------------------------- ----------- ---------
  Model 1: Risk factors multiply associated with all‐cause mortality                                                                                            
  Female sex                                                                                               0.80           0.66                      0.95        0.001
  Age (decades)                                                                                            1.74           1.57                      1.92        \<0.001
  Smoking status (ref. non‐smoker)                                                                                                                              
  Ex‐smoker                                                                                                1.15           0.97                      1.37        0.033
  Smoker                                                                                                   1.59           1.20                      2.09        \<0.001
  Diabetes mellitus                                                                                        1.28           1.09                      1.50        \<0.001
  Anaemia                                                                                                  1.27           1.07                      1.52        \<0.001
  log10(NT‐proBNP)                                                                                         2.10           1.83                      2.42        \<0.001
  CHD                                                                                                      1.40           1.18                      1.65        \<0.001
  Defibrillator                                                                                            1.53           1.10                      2.12        0.001
  Primary valve disease                                                                                    1.43           0.94                      2.17        0.030
  NYHA class (ref. no HF or NYHA I)                                                                                                                             
  II                                                                                                       1.97           1.51                      2.56        \<0.001
  III                                                                                                      2.33           1.74                      3.12        \<0.001
  IV                                                                                                       3.86           2.36                      6.32        \<0.001
  Medication                                                                                                                                                    
  Beta‐blockers                                                                                            0.72           0.60                      0.85        \<0.001
  Diuretics                                                                                                1.32           1.06                      1.65        0.001
  Model 2: Risk factors multiply associated with all‐cause mortality and hospitalization (first of both)                                                        
  Female sex                                                                                               0.86           0.74                      0.99        0.007
  Age (decades)                                                                                            1.48           1.37                      1.60        \<0.001
  Smoking status (ref. non‐smoker)                                                                                                                              
  Ex‐smoker                                                                                                1.08           0.94                      1.25        0.158
  Smoker                                                                                                   1.32           1.05                      1.65        0.002
  Diabetes mellitus                                                                                        1.25           1.09                      1.43        \<0.001
  CHD                                                                                                      1.23           1.02                      1.48        0.005
  History of MI                                                                                            1.26           1.04                      1.52        0.002
  NYHA class (ref. no HF or NYHA I)                                                                                                                             
  II                                                                                                       1.56           1.29                      1.91        \<0.001
  III                                                                                                      1.98           1.57                      2.48        \<0.001
  IV                                                                                                       3.31           2.11                      5.20        \<0.001
  log10(NT‐proBNP)                                                                                         1.61           1.43                      1.82        \<0.001
  Primary valve disease                                                                                    1.33           0.89                      2.00        0.066
  Defibrillator                                                                                            1.38           1.02                      1.88        0.006
  Anaemia                                                                                                  1.28           1.09                      1.50        \<0.001
  Medication with beta‐blockers                                                                            0.80           0.70                      0.93        \<0.001

CHD, coronary heart disease; HF, heart failure; NT‐proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart Association.

In particular, age \[HR = 1.48, 99% confidence interval (1.37, 1.60), *P* \< 0.001\] and clinical severity of HF, measured both in higher New York Heart Association (NYHA) class \[for NYHA II: HR = 1.56, 99% confidence interval (1.29, 1.91), *P* \< 0.001; for NYHA III: HR = 1.98, 99% confidence interval (1.57, 2.48), *P* \< 0.001; for NYHA IV: HR = 3.31, 99% confidence interval (2.11, 5.20), *P* \< 0.001\] and in higher NT‐proBNP levels \[for log10(NT‐proBNP) HR = 1.61, 99% confidence interval (1.43, 1.82), *P* \< 0.001\], were strong predictors of a reduced overall and hospitalization‐free survival. Male sex, age, smoking (both smokers and ex‐smokers), diabetes, coronary artery disease, and anaemia were also associated with reaching early one of the endpoints. Taking these factors into account, HoS showed no added information on the endpoints, that is, the effect of HoS is completely explained by the other factors.

4. Discussion {#ehf212605-sec-0015}
=============

In this analysis, we show that syncopes represent clinically a high‐risk profile among patients with HFrEF. Our data indicate the increased prevalence of HoS in patients with HF and a strong association of syncopes in patients with HFrEF with reduced overall and hospitalization‐free survival compared with patients with HFmrEF and HFpEF as well as controls without HF within a 10 year follow‐up. Our analysis is the first to focus on syncopes in a large HF population, including only pooled prospective data.

This is a highly relevant finding as risk assessment remains a main goal within HF diagnostics and therapy and the assessment of HoS adds significantly to an easily accessible characterization of this HF population.

While due to the study designs the causes for syncope were not recorded, the presence of HoS provides relevant information. Our multiple model calculations showed that the value of HoS as a predictive parameter is explained by the risk profile that patients with HFrEF with HoS suffer from, including co‐morbidities. They suffer from these risk factors more often and in a higher degree than patients with HFrEF without HoS, that is, patients with HFrEF with HoS are sicker than those without HoS. This highlights that HoS represents a clinically and easily accessible insight into a prognostic pattern for both the overall survival and the time to the first hospitalization.

History of syncope is like a multi‐parameter risk score providing not a number at high risk but a clinical symptom.

Exploring the outcome differences between the HFrEF, HFmrEF, and HFpEF groups, further investigation of the underlying pathophysiology of the syncopes is required, so we challenged our results with different interpretations.

With stroke volume being impaired in both HFrEF and HFpEF, reduced cardiac output is unlikely to describe the mechanism of action.

Regarding an arrhythmogenic genesis and potential sudden cardiac death, much has been debated about the significance of LVEF *per se* as a prognostic value, especially because the association of low LVEF with fatal arrhythmia or death from worsening HF is not proportional and controversial.[2](#ehf212605-bib-0002){ref-type="ref"}, [18](#ehf212605-bib-0018){ref-type="ref"} Recent trials showed the heterogeneous benefit from implantable cardioverter--defibrillator (ICD) therapy within the HFrEF population, for example, no benefit in non‐ischaemic cardiomyopathy, leaving the risk assessment in different cardiomyopathies to debate.[18](#ehf212605-bib-0018){ref-type="ref"} Our analyses explain the increased risk not monocausal but in a holistic approach, which is a representative clinical symptom.

In our cohort, patients with HoS were more likely to suffer from arrhythmia clearly evident in more implanted cardiac devices (ICD, right ventricular, and LV pacemakers) as well as history of resuscitation. Ruwald *et al*.[19](#ehf212605-bib-0019){ref-type="ref"} showed in patients with HFrEF with implanted ICDs that syncopes are, irrespective of the cause, indicators for increased mortality, and we could confirm this finding.

Autonomic dysfunction (AD) plays a major role in both sudden cardiac death and syncopes as well as in HF.[20](#ehf212605-bib-0020){ref-type="ref"} In addition, HF is also associated with chronotropic incompetence (CI).[21](#ehf212605-bib-0021){ref-type="ref"} CI leads to the limitation of physical activity and amplifies the HF symptoms. Unfortunately, we have only ECG results and have no access to the ECG raw data, holter ECG recordings, or cardiac stress tests, which constrains us in evaluating the influence of AD and CI on our results.

Casiglia *et al*.[22](#ehf212605-bib-0022){ref-type="ref"} showed that orthostatic hypotension (OH) correlates with cardiovascular co‐morbidities and provides a morbidity burden but without any impact on survival data. Because we do not have data from tilt testing or other diagnostic tools for OH, we cannot measure the value of OH, but we consider the impact of OH on our data very low because both hospital‐free and overall survival are affected in patients with HoS.

Moreover, because HF is characterized by upregulation of the sympathetic nervous system and abnormal responsiveness of the parasympathetic nervous system and that influences also AD as well as OH, we need to highlight an increase in cardiac adrenergic drive as a potential origin of syncopes.[23](#ehf212605-bib-0023){ref-type="ref"} Both chronotropy and inotropy are altered by the level of adrenergic drive and make the circulation susceptible for sudden changes and syncopes through limited response in heart rate and blood pressure. This system is altered not only by HF but also by medication. Particularly, beta‐blockers aim to reduce the sympathetic effect on the heart and are a recommended therapy for patients suffering from HFrEF. As a result, patients suffer from an iatrogenic chronotropic incompetence and reduced blood pressure, both relevant factors in the origin of syncopes.[24](#ehf212605-bib-0024){ref-type="ref"} Furthermore, adrenergic receptors of the vasculature are key not only to cardiac syncopes but also to neurally mediated syncopes---not to differentiate in our cohort as we do not have any information on the origin.[25](#ehf212605-bib-0025){ref-type="ref"}, [26](#ehf212605-bib-0026){ref-type="ref"} In our cohort, blood pressure did not show a relevant association with the endpoints and was omitted from the risk model. Beta‐blockers showed an effect on the survival endpoint. We see this finding in the context of patients with HFrEF with HoS showing a worse outcome than patients with other HF entities, and beta‐blockers are more frequently taken among patients with HFrEF than among others. At the same time, these patients suffer probably more often by the side‐described side effects of beta‐blockers; beta‐blockers explain the syncopes only partially in our risk model.

Furthermore, HF medication *per se*, for example, angiotensin‐converting enzyme inhibitors, also triggers syncopes as a side effect.[27](#ehf212605-bib-0027){ref-type="ref"} A Danish register study revealed a substantial association between cardiovascular pharmacotherapy and syncopes.[28](#ehf212605-bib-0028){ref-type="ref"} Likewise, the Danish study confirmed that the cardiovascular risk factors such as chronic kidney disease, anaemia, diabetes, and other co‐morbidities are associated not only with cardiovascular mortality but also with HoS, and we could show this in a prospective HF population.

4.1. Study limitations {#ehf212605-sec-0016}
----------------------

However, as stated, the present study has several limitations. The limitations primarily involve the study population and the validity of the registered HoS. This analysis of pooled data by the German CNHF, like any other study, deals with the possibility of unmeasured confounding biases while providing access to a large number of patients. In particular, considering the total network population, although studies were harmonized within the framework, they still were different, including different inclusion and exclusion criteria, biomarker assay methods, and reported parameters. All subjects were seen at sites conducting studies of the German CNHF; therefore, the study population despite its size is not equivalent to real‐world data. These effects are set against a long follow‐up and a high quality of the endpoint data because they were registered in studies and were not from registries. Regarding the validity of HoS, the major limitation refers to the fact that the syncopes were not categorized based on pathophysiological causes in the databases. Hence, we do not have data on further aetiological work‐up of these syncopes.

5. Conclusions {#ehf212605-sec-0017}
==============

We show for the first time that syncopes represent a high‐risk profile and poorer overall and hospital‐free survival in a large HF cohort from several prospective studies, resulting in a higher mortality and a shorter hospital‐free survival especially in the HFrEF cohort compared with the HFmrEF group, the HFpEF group, or the controls without HF.

This is highly relevant because this finding offers a better and easily accessible characterization of the HF cohort; HoS may change diagnostic and therapeutic decisions regarding closer follow‐ups and further risk assessment.

The pathophysiology of HoS remains undefined, while it is a valuable predictor for overall and hospitalization‐free survival in patients with HF. Noting this should include HoS in the standard evaluation of every patient. HoS shows a high‐risk profile for mortality and hospitalization in the HFrEF cohort.
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Inclusion criteria: Completed basic clinical dataset

Exclusion criteria: No echocardiography details on left ventricle ejection fraction or E/e′Aortic valve stenosisNo laboratory details on serum electrolytes, haemoglobin or creatinineNo details on blood pressureNo details on co‐morbiditiesNo details on implanted implantable cardioverter--defibrillator or pacemaker devicesNo electrocardiogram detailsPrevious resuscitationRegular alcohol consumption
